Analysts Are Bullish on These Healthcare Stocks: CRVS, GLYC

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals Inc (NASDAQ: CRVS) and GlycoMimetics (NASDAQ: GLYC) with bullish sentiments.

Corvus Pharmaceuticals Inc (NASDAQ: CRVS)

In a report released yesterday, Boris Peaker from Cowen & Co. assigned a Buy rating to Corvus Pharmaceuticals Inc (NASDAQ: CRVS). The company’s shares opened today at $12.32.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.2% and a 43.1% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Iovance Biotherapeutics Inc, and Merrimack Pharmaceuticals.

Corvus Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25.

GlycoMimetics (NASDAQ: GLYC)

In a report released yesterday, Ritu Baral from Cowen & Co. assigned a Buy rating to GlycoMimetics (NASDAQ: GLYC). The company’s shares opened today at $11.59.

Baral said:

“GLYC reported Q3 losses in line with expectations and a balance sheet strengthened.”

According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.2% and a 52.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on GlycoMimetics is Strong Buy and the average price target is $19.75, representing a 70.4% upside.

In a report issued on November 1, Roth Capital also reiterated a Buy rating on the stock with a $25 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.